Proteomics

Dataset Information

0

DOT1 Like Histone Lysine Methyltransferase (DOT1L) and Menin 1 (MEN1) interaction proteomics in breast cancer cell nuclei

ABSTRACT: Estrogen Receptor alpha (ERα) is a ligand-inducible transcription factor that mediates estrogen signaling in hormone-responsive breast cancer (BC) and is the primary target of specific anticancer therapies that although effective can generate resistance phenomena that represents a crucial problem in clinical management of patients affected by this disease. DOT1 Like Histone Lysine Methyltransferase (DOT1L) and Menin 1 (MEN1) have been identified as functional component of the ERα mechanism of action. To investigate the involvement of DOT1L and MEN1 in mediating ERα actions in hormone-responsive and endocrine-resistant BC, interaction proteomics was applied to map the DOT1l and MEN1 nuclear interacting partners in MCF7 breast cancer cell nuclei in order to the identifiy new possible therapeutic targets for a more effective pharmacological treatment of endocrine therapy-resistant tumors.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Tuula Nyman  

LAB HEAD: Tuula Nyman

PROVIDER: PXD026864 | Pride | 2022-08-12

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.

Salvati Annamaria A   Melone Viola V   Sellitto Assunta A   Rizzo Francesca F   Tarallo Roberta R   Nyman Tuula A TA   Giurato Giorgio G   Nassa Giovanni G   Weisz Alessandro A  

Breast cancer research : BCR 20220718 1

<h4>Background</h4>Targeting vulnerabilities of cancer cells by inhibiting key regulators of cell proliferation or survival represents a promising way to overcome resistance to current therapies. In breast cancer (BC), resistance to endocrine therapy results from constitutively active or aberrant estrogen receptor alpha (ERα) signaling to the genome. Targeting components of the ERα pathway in these tumors represents, therefore, a rational way toward effective new treatments. Interaction proteomi  ...[more]

Similar Datasets

Proteomics Estrogen Receptor alpha and Histone Lysine Methyltransferase DOT1L chromatin bound interactome
2019-02-09 | PXD010314 | Pride
Transcriptomics Functional effect of DOT1L pharmacological inhibition in ERα-positive Ovarian Cancer cells
2019-11-04 | E-MTAB-8198 | biostudies-arrayexpress
Transcriptomics Inhibition of the histone methyltrasferares DOT1L deregulates hormone responsive breast cancer cells methylome
2023-02-21 | E-MTAB-12635 | biostudies-arrayexpress
Proteomics Nuclear Estrogen Receptor alpha (ERα) interactome following estrogen and antiestrogen treatment.
2020-09-02 | PXD018709 | Pride
Unknown Estrogen Receptor Beta Impacts Hormone-Induced Alternative mRNA Splicing in Breast Cancer Cells
2015-09-01 | GSE64590 | GEO
Transcriptomics DNA methylation of estrogen regulated enhancers defines endocrine sensitivity in breast cancer
2015-07-01 | E-GEOD-69118 | biostudies-arrayexpress
Proteomics Estrogen Receptor beta (ERβ) interactome in triple negative breast cancer cells nuclei
2019-12-03 | PXD014468 | Pride
Proteomics Estrogen Receptor alpha (ERα) interactome before and after RNAse treatment in human breast cancer cells nuclei
2019-07-29 | PXD012630 | Pride
Unknown Growth Factor Stimulation Induces a Distinct ERα Cistrome Underlying Breast Cancer Endocrine Resistance
2010-12-29 | GSE26081 | GEO
Proteomics,Multiomics Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha
2019-03-21 | PXD012930 | Pride